The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | MINOTAUR: lunresertib with FOLFIRI in CCNE1 and FBXW7 mutated GI cancers
Elisa Fontana, MD, PhD, Sarah Cannon Research Institute, London, UK, discusses the Phase I MINOTAUR study (NCT05147350) of lunresertib, a PKMYT1 inhibitor, with FOLFIRI in advanced gastrointestinal (GI) cancers with CCNE1 amplification or FBXW7 mutations. Treatment-related adverse events were consistent with FOLFIRI alone and the overall response rate was promising, especially in heavily pretreated patients. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
